Planned name change to hVIVO plc
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its intention to change its name to hVIVO plc, with the change expected to take effect on 26 October 2022.
The Board believes that the name change reflects the Company’s core human challenge and early clinical services business, where the hVIVO name has strong global brand recognition within the biopharma industry and beyond, as well as aligning the Company more closely with its long and established heritage.
The Company’s new ticker will be HVO as of 26 October 2022 and the website address (including the investor relations content and the information required by AIM Rule 26) will be available at www.hvivo.com
The Company’s ISIN (GB00B9275X97) and SEDOL (B9275X9) will remain the same.
Shareholders will be unaffected by the change of name and existing share certificates should be retained and will remain valid. Any new share certificates issued after the name change takes effect will bear the name hVIVO plc.
For further information please contact:
Open Orphan plc
+44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is changing its name to hVIVO plc (AIM and Euronext: HVO), which is expected to take effect on the AIM market of the London Stock Exchange and the Euronext Growth Exchange market on 26 October 2022.
hVIVO is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned